Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE: Long-Term Safety and Tolerability of Seladelpar in PBC
NCT03301506Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2017
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Started Dec 2017; status: active, not recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03301506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301506.